This review highlights the increased risk of cardiovascular disease and the dismal prognosis after acute coronary events when diabetes is present. Although there have been improvements in this area, diabetes still confers an increased risk. In order to achieve successful outcomes in individuals with diabetes, extensive treatment of risk factors and the use of all available evidence-based therapies are needed. In this context, glucose-lowering therapies and antithrombotic and revascularisation strategies are detailed in this review. Emerging data indicate that novel glucose-lowering drugs may impact cardiovascular outcome with mechanisms that are beyond glucose control. In addition, this review addresses hidden diabetes and impaired glucose tolerance in patients with acute and stable coronary artery disease and how they influence future cardiovascular risk.
Prevalence of abnormal glucose regulation
The prevalence of previously known diabetes among patients with acute coronary syndromes (ACS) has increased the later decades parallel to the increase in diabetes prevalence seen in the general population and due to the improved life-expectancy in diabetes individuals. 1, 2 The prevalence varies between 20% and 30%, with lower proportions in the Scandinavian countries and higher proportions among Central and Eastern European countries and in the USA. [3] [4] [5] By contrast, in clinical randomised trials, the prevalence of patients with diabetes tends to be lower because of inclusion/exclusion criteria that often exclude the most severely compromised patients. Hyperglycaemia is often present in patients with ACS and was already described in 1929 by Levine, who reported high levels of glucose in the urine of patients with acute coronary thrombosis. For a long time, this finding was mainly attributed to the stressful situation caused by an acute event. 6 However, more recent studies with repeated glucose evaluations by means of standardised oral glucose tolerance tests (OGTTs) in acute myocardial infarction (AMI) and in stable coronary artery disease (CAD) populations demonstrated that undiagnosed diabetes and impaired glucose tolerance (subsequently named together as abnormal glucose tolerance [AGT] ) are common, persist over time and likely precede the event. Approximately 60-65% of CAD patients present with AGT when screened with an OGTT, while a large part of them would remain undiagnosed if HbA 1c or fasting plasma glucose (FPG) were used as screening tools. [7] [8] [9] [10] [11] The latest joint guidelines from the European Society of Cardiology (ESC) and the European Study of Diabetes (EASD) recommend that screening for potential type 2 diabetes mellitus in people with cardiovascular disease (CVD) is initiated with HbA 1c and FPG, and that an OGTT should be added if HbA 1c and FPG are inconclusive ( Figure 1) . 11 It is of importance not to perform an OGTT too early in the course of an AMI, but to wait 4-5 days after an acute event in order to minimise the influence of stress. 8, 11 Prognosis after ACS in the presence of abnormal glucose regulation Diabetes has for a long time been a recognised risk factor for AMI. In the 1970s, the Framingham Study showed that diabetes conferred a two-to four-times greater risk for MI and a four-to six-times greater risk for heart failure. 12 The INTERHEART study confirmed this two-to four-times greater risk for MI on a global scale. 13 Parallel to the emerging overall decrease in MI and cardiovascular (CV) mortality in the Western world, there seems to have also been a reduction in the MI risk associated with diabetes (of one-to two-times), although with a greater impact on younger ages and a lesser impact on older ages. [14] [15] [16] National reports and registry studies show impressive reductions in mortality after AMI in patients both with and without diabetes, but there is still a significant gap between these two populations ( Figure 2) . 3, 17 Such a reduction in mortality rate is due to an increased implementation of secondary prevention measures, as well as revascularisation of the acute coronary occlusion. 3, 11, 18 However, there are signals that we are far from an optimal use of state-of-the-art treatment strategies in patients with diabetes. 3, 11, 19, 20 The under-use of evidence-based therapies in diabetic patients with ACS could be related to a different clinical presentation, with silent ischaemia, more diffuse symptoms or symptoms mixed with hypoglycaemia resulting in late admission for/diagnosis of AMI. Another factor could be a form of physician-related hesitancy to utilise intensive treatment because of the increased vulnerability of patients when diabetes is present. However, it is established that therapeutic strategies including b-blockers, statins, antithrombotic therapies and early revascularisation in the setting of an AMI are effective in patients both with and without diabetes, and the prognosis is much more severe if evidence-based therapies are withheld. 3, 11, 21, 22 The most recent recommendations on how to prevent CV complications in diabetic individuals are summarised in Figure 3 . 21 In diabetes, the choice and impact of glucose-lowering and antithrombotic therapies as well as revascularisation strategies after ACS are of importance, and these are extensively discussed below. Since patients with diabetes today survive AMIs to a much greater extent, there will be a higher number of diabetic individuals with chronic ischaemic heart disease. In unselected registry populations, diabetes confers a successively increasing risk for CV complications beyond the first year after the acute event. Common complications, apart from increased long-term mortality, are hospitalisation for heart failure and re-infarction. 23 This risk is more pronounced in the presence of insulin therapy and long-standing diabetes. 14, 21, 22, 23 Long-term follow-up studies of CV complications in CAD patients with glucose abnormalities are now being reported. 24, 25 A small cohort study found that newly discovered AGT in the presence of established CAD predicts CV mortality and morbidity ( Figure 4) . 24 This indicates that an OGTT after an AMI may be useful for identifying individuals at increased CV risk rather than for diagnosing diabetes. According to the most recent guidelines, when these individuals are identified, secondary prevention and lifestyle changes should be implemented. 21 Glucose control in acute and stable CAD In the setting of ACS, elevated plasma glucose or HbA 1c are associated with worse prognosis. 11, 26 The hypothesis that glucose lowering in this setting would improve prognosis was tested in the randomised Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) trial. 26 A total of 620 patients were randomised to intensified insulinbased glycaemic control including 24-hour insulin-glucose infusion (with the aim of stabilising blood glucose at between 7 and 10.9 mmol/L) followed by multi-dose insulin or standard glucose lowering. After 3.4 years, an 11% absolute risk reduction in mortality was obtained. 26 These positive results were not confirmed in the DIGAMI 2 trial. 27 One reason for the discrepant results between DIGAMI 1 and DIGAMI 2 is the lack of difference in glucose levels between the intensified insulin-based group and the control group achieved in the latter trial. Another explanation is that blood glucose and HbA 1c at admission were substantially higher in DIGAMI 1 as compared to DIGAMI 2 (mean blood glucose 15.4 vs. 12.8 mmol/L and HbA 1c 8.2% vs. 7.2%, respectively). Moreover, the overall mortality rate was lower in DIGAMI 2 due to more extensive treatment with evidence-based therapies, such as statins and revascularisation. In the acute setting, insulin has been studied not only for improving glucose levels, but also for stopping the myocardial metabolic vicious circle that is triggered during an ischaemic event. 28 However, randomised trials using a glucose-insulinpotassium (GIK) infusion, glucose-insulin or only insulin have not shown consistent mortality or morbidity reductions, as thoroughly reviewed by Kloner and Nesto. 29 Possible explanations for these negative results are volume overload caused by the GIK infusion, increases in glucose levels or late administration of the insulin infusion when negative metabolic effects were already established. 28, 29 Current ESC guidelines recommend (class IIa, level of evidence C) that insulin-based glycaemic control should be considered only in ACS patients with significant hyperglycaemia (>10 mmol/L or >180 mg/dL), with awareness of the increased risk of hypoglycaemia in patients with comorbidities such as malnutrition and renal insufficiency.
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In stable CAD, the recommended glycaemic target is HbA 1c 7% (53 mmol/mol), but an individualised treatment is emphasised by most recent guidelines. 11, 21, 22 Accordingly, in elderly patients, in those with long-standing diabetes or in those with established CVD, intensive glucose lowering may even be harmful. 30 The target is therefore less strict (<7. Lifestyle changes including smoking cessation, low fat diet, high fibre diet, aerobic physical activity, and strength training are recommended.
Reduction in energy intake is recommended to patients to help achieve lower weight or prevent weight gain.
A target HbAIc for the reduction in risk of CVD and microvascular complications in DM of <7.0% (<53 mmol/mol) is recommended for the majority of non-pregnant adults with either type I or type 2 DM.
A target HbAIc of ≤6.5% (≤48 mmol/mol) should be considered at diagnosis or early in the course of type 2 DM in patients, who are not frail and do not have CVD.
When screening for DM in individuals with or without CVD, assessment of HbAIc (which can be done non-fasting) or fasting blood glucose should be considered. An oral glucose tolernce test can be offered when there is still doubt.
Metformin is recommended as first-line therapy, if tolerated and not contra-indicated, following evaluation of renal function.
Avoidance of hypoglycaemia and excessive weight gain should be considered and individual approaches (with respect to both treatment targets and drug choices) should be considered in patients with advanced disease.
In patients with type 2 DM and CVD, the use of an SGLT2 inhibitor should be considered early in the course of the disease to reduce CV and total mortality.
Lipid lowering agents (prinicipally statins) are recommended to reduce CV risk in all patients with type 2 or type I DM above the age of 40 years.
Lipid lowering agents (prinicipally statins) may be considered also in individuals below 40 years of age if at significantly elevated risk, based on the presence of micro-vascular complications or of multiple CV risk factors.
The use of drugs that increase HDL-C to prevent CVD in type 2 DM is not recommended.
Antiplatelet therapy (e.g. with aspirin) is not recommended for people with DM who do not have CVD.
In DM patients at very high-risk (see table 5 BP targets in type 2 DM are generally recommended to be < 140/85 mmHg, but a lower target of < 130/80 mmHg is recommended in selected patients (e.g. younger patients at elevated risk for specific complications) for additional gains on stroke, retinopathy and albuminuria risk. Renin-angiotensin-aldosterone system blocker is recommended in the treatment of hypertension in DM, particularly in the presence of proteinuria or micro-albuminuria. Recommended BP target in patients with type 1 DM is < 130/1/80 mmHg.
For patients with a long duration of DM, the elderly, frail, or those with existing CVD, a relaxing of the HbAIc targets (i.e. less stringent) should be considered. non-inferiority but not superiority with respect to CV risk; there was, however, an increased rate of hospitalisation with saxagliptin. 21, 22 There has been a very recent paradigm shift, with last-generation glucoselowering agents showing significant reductions in CV events in outcome trials/ In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) outcome trial, the SGLT2 inhibitor empagliflozin reduced CVD death, all-cause mortality and hospitalisation for heart failure; in the LEADER trial, the GLP-1 receptor agonist liraglutide reduced CV death and allcause mortality; and finally, in the trial to evalutate cardiovascular and other long-term outcomes with semaglutide in subjects with Type 2 Diabetes (the SUSTAIN-6 trial), the long-acting GLP-1 inhibitor semaglutide reduced CV events. These positive results seem to be related to mechanisms beyond the glucoselowering effect, and more research is needed in order to understand these trial results.
Antithrombotic therapy
Although platelet reactivity is a major feature in patients with diabetes, the benefits of aspirin in diabetes subjects without established CVD remain inconclusive. 32 In order to better determine whether aspirin plays any beneficial role in the primary prevention of CVD in diabetes, the ongoing A Study of Cardiovascular Events in Diabetes (ASCEND) trial has enrolled over 15,000 patients with plans to complete the study within the next couple of years. Additionally, the Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D) trial has a planned enrolment of 5170 patients, evaluating the benefit of aspirin plus statin versus statin alone. These trials should help to define the risk-benefit ratio of lowdose aspirin in this setting. In secondary prevention, aspirin treatment is similarly effective in patients with and without diabetes mellitus. Data from the Antiplatelet Trialists' Collaboration on more than 45,000 diabetes patients showed that antiplatelet therapy reduces major CV events by 25%. 33 Hence, the use of aspirin is highly recommended in diabetes patients with a history of CVD. 11 The P2Y12 receptor plays a central role in platelet aggregation. Blockade of this receptor represents a valid strategy for preventing atherothrombotic complications in diabetes. 11, 34 In the diabetes subgroup of the clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) trial, in which patients with CAD, cerebrovascular disease or peripheral artery disease were randomised to aspirin or clopidogrel, an absolute risk reduction was observed that was significantly larger than in subjects without diabetes. 11, 34 However, in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial, the addition of clopidogrel to aspirin did not demonstrate any further benefit than aspirin alone in the prevention of CV outcomes. 11, 34 On the other hand, the CURE trial demonstrated the benefit of a reduction in atherothrombotic events with the addition of clopidogrel to aspirin after ACS in those both with and without diabetes. 11, 34 The P2Y12 inhibitors prasugrel (irreversible) and ticagrelor (reversible) have been shown to be highly effective in diabetes patients with ACS, and may be preferred to clopidogrel in patients with ACS undergoing percutaneous coronary intervention (PCI). Indeed, in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) study, diabetes subjects tended to have a greater reduction in ischaemic events without an observed increase in major bleeding. 34 These data demonstrate that the more intensive oral antiplatelet therapy provided with prasugrel is of particular benefit to patients with diabetes. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor equally reduced the rate of ischaemic events in ACS patients both with and without diabetes. 35 Most recent guidelines suggest that the Dual antiplatelet treatment (DAPT) should be continued for up to at least 12 months, but a longer duration is under investigation. 34 The use of glycoprotein (GP) IIb/IIIa inhibitors is not supported by current evidence, except for in high-risk patients. 35 In diabetic patients, trials performed without concomitant use of thienopyridines have been shown to have a favourable impact on outcomes. 34 Since a high clopidogrel loading dose was not present in the design of these studies, the data obtained remain questionable. The early eptifibatide therapy in non-STsegment elevation acute coronary syndrome (EARLY-ACS) trial showed that administration of eptifibatide before angiography in non-ST-elevation myocardial infarction (NSTEMI) was not superior to its use after PCI. 34 Furthermore, the early use of eptifibatide was associated with an increased risk of non-life-threatening bleeding. However, the efficacy of GP IIb/IIIa inhibitors correlates with the severity of the ACS, and the risk-benefit ratio should always be assessed in an individualised manner. 34 Accordingly, the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial demonstrated that abciximab compared to placebo after pre-treatment with clopidogrel reduces adverse events in patients with high-risk ACS undergoing PCI. 11, 34 Therefore, diabetes patients with NSTEMI and high troponin release should be treated with GP IIb/IIIa inhibitors, if the bleeding risk is acceptable. In STEMI patients, the benefits of GP IIb/IIIa inhibitors are controversial, and there are conflicting results in diabetes. A meta-analysis of 16 randomised trials showed that GP IIb/IIIa inhibitors did not reduce 30-day mortality or re-infarction, but were associated with a higher risk of major bleeding complications. 11 Mortality was reduced in high-risk ACS, but not reinfarction. In contrast, the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial conducted in lowrisk ACS patients with diabetes did not show any benefit with the use of abciximab after balloon angioplasty or stenting.
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Anticoagulants
The available evidence indicates that anticoagulation is effective in addition to platelet inhibition and that the combination of the two is more effective than either treatment alone. 34 Fondaparinux, an indirect factor Xa inhibitor, has been shown to be non-inferior to low-weight molecular heparin (LWMH) at reducing the risk of ischaemic events. The he Pentasaccharide in Unstable Angina (PENTUA) and the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trials have demonstrated that the major advantage of fondaparinux is the low risk of major bleeding with a consistent reduction of short-and long-term morbidity and mortality. 34 An analysis exploring the uptake of fondaparinux compared with LMWH among 40616 NSTEMI patients from a largescale Scandinavian registry reported fewer in-hospital mortality and bleeding events associated with the use of fondaparinux, while the reductions of CV mortality at 30 and 180 days were comparable in the two groups. 35 Overall, fondaparinux is considered to be the parenteral anticoagulant with the most favourable efficacy-safety profile and is now recommended as a first-line anticoagulant in ACS patients. 34 In a diabetes subgroup analysis of the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial, monotherapy with the direct thrombin inhibitor bivalirudin was associated with similar rates of death, MI or unplanned ischaemic revascularisation compared with GP IIb/IIIa plus heparin, but with a lower rate of major bleeding. These findings are of importance since diabetes per se is a predictor of bleeding complications in patients with ACS undergoing PCI. 34 In conclusion, fondaparinux and bivalirudin might be preferred in diabetic patients due to the lower risk of bleeding complications.
Revascularisation
An important part of the secondary preventive programme in patients with diabetes includes the revascularisation of affected coronary arteries if there are signs of myocardial ischaemia. 36 An early revascularisation strategy improved survival after hospitalisation for unstable angina and reduced re-infarctions in diabetic individuals in the Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC) 2 trial, which was conducted before the stents era. Registries indicate a tendency towards underuse of revascularisation among patients with diabetes and established ischaemic heart disease, who more often have no recorded revascularisation procedure than those without diabetes. 20, 23 The preference of the patient, a complex CAD configuration and no remaining signs of myocardial ischaemia could also interfere with this. Whatever the reasons, an increased awareness of the problem is needed, since prognosis might be influenced. 20, 36 The guidelines state that choice of revascularisation strategy (PCI or coronary artery bypass grafting [CABG]) should be implemented after a risk-benefit evaluation of a multidisciplinary heart team. 11, 36 CAD is often more extensive and diffuse if diabetes is present, 4, 11, 35, 36 with an increased tendency to restenosis, stent thrombosis and graft occlusion, especially in those treated with insulin. 11, 23, 34, 36 The introduction of mammary artery grafts, bare-metal stents (BMSs) and drug-eluting stents (DESs) has, however, improved patency after revascularisation in those with diabetes. The use of DESs instead of BMSs further lowers the restenosis rate in diabetes. 37 The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial and the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial suggest a preference for CABG over PCI in patients with diabetes and multivessel disease due to the lower rate of major CV events and improved long-term mortality with CABG in this setting. 38, 39 The choice of PCI with a DES can, however, be considered in less extensive CAD and when the SYNTAX score is low. 11, 39 In everyday practise, the configuration of the coronary artery stenosis may be difficult to target with revascularisation. In this setting, intense secondary prevention is strongly recommended. In patients with depressed left systolic ventricular function due to two-or threevessel CAD, there are indications based on the recent long-term follow-up of the Surgical Treatment for Ischemic Heart Failure (STICH) trial that prognosis might be improved by revascularisation with CABG. Since the evidence is sparse, the most recent guidelines on revascularisation state that the assessment of viability should not be the sole factor when deciding on the best strategy for patients with severe left ventricular function and evident CAD. 39 
Lifestyle intervention
In recent years, several guidelines on diabetes and on CVD have stressed the importance of addressing lifestyle habits in high-risk individuals. 21, 22 The most important changes to be implemented are smoking cessation, increased physical activity and healthy diet patterns, and avoid alcohol over consumption. Furthermore, psychosocial risk factors should be explored, as they might interfere with the possibility of succeeding with lifestyle changes. Small changes in body weight can indeed improve glucose control. Short intervals from long-term sitting ('brakers'), with two minutes of standing/walking every 20 minutes, have been shown to improve glucose and insulin levels. Figure 3 reviews important lifestyle interventions in diabetes. Mainly, a Mediterranean diet pattern including fruits, vegetables, legumes, olive oil and fish is advocated. Patients with type 2 diabetes obtain a great benefit by limiting saturated and trans fats and alcohol intake, monitoring carbohydrate consumption and increasing dietary fibre. In the the PREvencio´n con DIeta MEDiterra´nea (PREDIMED) study, which investigated individuals at high CV risk, including 40% with diabetes, a Mediterranean diet pattern and extra portions of olive oil or nuts reduced CV events, mortality and the development of diabetes. 21 In the Steno 2 trial, CV complications and mortality were reduced in type 2 diabetes patients with multifactorial treatment, including lifestyle changes. 18 
Conclusion
In recent decades, type 2 diabetes patients have achieved longer life expectancy, better outcomes after myocardial infarction and a reduction in CV mortality. This depends on CV prevention, multifactorial treatment and improved management of acute and stable CAD. However, CVD remains the most common cause of mortality, and complications such as heart failure are increasingly common in this setting. Further research and intensive management are mandatory in order to prevent diabetes development and the risk of CV complications in patients with established type 2 diabetes.
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